Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Stop Yakkasa-Based Business Immediately: FPMAJ President Morita
February 4, 2008
- Korosho Considers Joint Clinical Trial Consultation Services with the US and EU
February 4, 2008
- Preminent Most Heavily Promoted in December: Rep Track Survey
February 4, 2008
- Insurance Policies to Be Required for Clinical Research
February 4, 2008
- BUSINESS NEWS IN BRIEF
February 4, 2008
- Council Moving to Build Up Regional Clinical Trial Systems
February 4, 2008
- NEW PRODUCTS
February 4, 2008
- Public Opinions Invited on Draft Guidance on MD Studies
February 4, 2008
- GENERICS NEWS IN BRIEF
February 4, 2008
- Article 35 of the Amended Patent Law Should Be Properly Applied: Dr Akimoto
February 4, 2008
- How Can We Maximize the Value of Our Brand？
February 4, 2008
- R&D NEWS IN BRIEF
February 4, 2008
- Outline of FY2008 Revision of Medical Fees Approved by Chuikyo
February 4, 2008
- Cardiac Reagent NT-proBNP: RDKK
February 4, 2008
- Re-Pricing for Market Expansion Discourages Investment: PhRMA
February 4, 2008
- SELF-MEDICATION NEWS IN BRIEF
February 4, 2008
- 13 APIs Receive Approval Including Nexavar and Champix
February 4, 2008
- Risk of Death Decreases with Increases in Total Cholesterol Levels: Prof Hamazaki
February 4, 2008
- 42 New Technologies, 24 "Advanced Medical Technologies" Recommended for Insurance Coverage
February 4, 2008
- Precautions on "Impaired Performance" Necessary for Antihistaminics: sanofi-aventis
February 4, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…